v3.26.1
ADDITIONAL BALANCE SHEET DETAIL - Schedule of Accrued Expenses and other Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Product revenue allowances excluding rebates $ 5,568 $ 7,916
Product rebates 68,893 64,674
Product return provisions, current portion 1,694 2,375
Clinical trial costs 1,446 1,188
Compensation and related benefits 7,348 11,018
Operating lease liabilities $ 1,006 $ 3,548
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
Royalties due to Panion & BF Biotech, Inc. $ 2,458 $ 3,924
Professional fees 1,572 1,597
Accrued manufacturing costs 2,362 1,808
Restructuring costs 1,688 0
Liability related to sale of future royalties, current portion 1,450 1,664
Settlement royalties liability, current portion 9,624 12,516
Payments due to Q32 Bio Inc. 2,000 5,000
Other 2,688 4,488
Total accrued expenses and other current liabilities $ 109,797 $ 121,716